Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Phase II study to evaluate the efficacy of regorafenib in metastatic colorectal cancer patients by the assessment using FDG-PET/CT (JACCRO CC-12) metastatic colorectal cancer (JACCRO CC-12)

Date

08 Oct 2016

Session

Poster Display

Presenters

Hironaga Satake

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

H. Satake1, M. Nakamura2, A. Tsuji3, T. Sagawa4, F. Tamura4, Y. Hatachi3, K. Oguchi5, A. Takagane6, T. Kaji7, T. Sekikawa8, M. Furukawa2, M. Kochi9, W. Ichikawa8, M. Takeuchi10, M. Fujii9, T. Nakajima11

Author affiliations

  • 1 Department Of Medical Oncology, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 2 Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto/JP
  • 3 Department Of Medical Oncology, Kobe City Medical Center General Hospital, Kobe/JP
  • 4 Department Of Gastroenterology, Hokkaido Cancer Center, Sapporo/JP
  • 5 Positron Imaging Center, Aizawa Hospital, Matsumoto/JP
  • 6 Department Of Surgery, Hakodate Goryoukaku Hospital, Hakodate/JP
  • 7 Pet Center, Hakodate Goryoukaku Hospital, Hakodate/JP
  • 8 Division Of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama/JP
  • 9 Department Of Digestive Surgery, Nihon University School of Medicine, Tokyo/JP
  • 10 Department Of Clinical Medicine (biostatistics), Kitasato University School of Pharmacy, Tokyo/JP
  • 11 Gastroenterology, Japan Clinical Cancer Research Organization, Tokyo/JP
More

Resources

Abstract 2284

Background

Regorafenib (REG) have been approved as salvage treatment for patients with metastatic colorectal cancer (mCRC). Tumor metabolic analysis using FDG-PET/CT has been reported to be more sensitive to predict the response of molecular targeting agents, as compared with the change of tumor burden using conventional CT. We conducted a prospective study to evaluate the efficacy of REG in mCRC patients by the assessment using FDG-PET/CT.

Methods

Patients with mCRC refractory to standard chemotherapies with measurable lesions according to RECIST (Ver. 1.1) criteria, which are also assessable by FDG-PET/CT, enrolled in this study. REG was given orally in a dose of 160 mg once-daily for 3 weeks, followed by 1 week of rest. After the first cycle, FDG-PET/CT was performed again to assess the chronological change in the SUV max as compared with that before the treatment. The primary endpoint is the chronological change in SUV max in the legion, of which value is highest in pretreatment FDG-PET/CT. Metabolic response and size-based response were assessed according to EORTC PET and RECIST criterion, respectively, by independent external review. We set the null and alternative hypotheses at 0% and 10%, respectively. Assuming a one-sided alpha level of 2.5% and a power of ≥90%, we estimated that 16 subjects are required and set the target sample size at 20 patients.

Results

From November 2014 to March 2016, 17 of all enrolled 20 patients were evaluated for metabolic response. Six and 11 patients had SD and PD for the best overall response according to the RECIST criteria, thus the DCR was 30.0% (95% CI, 11.9-54.3). As for the primary endpoint, the response rate was 5.9% (95% CI, 0.1-28.7) in all evaluable patients including one PR, 4 SD (23.5%) and 12 PD (70.6%). Based on the chronological changes of the sum of SUV max in all targeted legions up to 5, there were 5 SD (29.4%) and 12 PD (70.6%). When response was categorized into PD and non-PD (PR or SD), the metabolic response after the first cycle could predict the size-based response with a sensitivity of 83% and specificity of 100%.

Conclusions

We confirmed the efficacy of REG in mCRC patients by the assessment of metabolic response using FDG-PET/CT.

Clinical trial identification

UMIN000015563, Nov 01 2014

Legal entity responsible for the study

Masato Nakamura

Funding

Bayer

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings